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Calciﬁcationetyl-alpha-D-galactosamine: polypeptide N-acetylgalactosaminyl-transferarase 3
(ppGalNacT3), a glycosyltransferase which has been suggested to prevent proteolysis of FGF23, a potent
phosphaturic protein. Accordingly, loss-of-function mutations in GALNT3 cause hyperphosphatemic familial
tumoral calcinosis (HFTC), a rare autosomal recessive disorder manifesting with increased kidney
reabsorption of phosphate, resulting in severe hyperphosphatemia and widespread ectopic calciﬁcations.
Although these ﬁndings deﬁnitely attribute a role to ppGalNacT3 in the regulation of phosphate homeostasis,
little is currently known about the factors regulating GALNT3 expression. In addition, the effect of decreased
GALNT3 expression in peripheral tissues has not been explored so far. In the present study, we demonstrate
that GALNT3 expression is under the regulation of a number of factors known to be associated with
phosphate homeostasis, including inorganic phosphate itself, calcium and 1,25-dihydroxyvitamin D3. In
addition, we show that decreased GALNT3 expression in human skin ﬁbroblasts leads to increased expression
of FGF7 and of matrix metalloproteinases, which have been previously implicated in the pathogenesis of
ectopic calciﬁcation. Thus, the present data suggest that ppGalNacT3 may play a role in peripheral tissues of
potential relevance to the pathogenesis of disorders of phosphate metabolism.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Inorganic phosphate (Pi) is an element of essential importance for
skeletal mineralization, mineral homeostasis, and a wide range of
cellular processes involving signaling and synthesis of energy-
generating compounds. Pi dietary intake, renal and intestinal absorp-
tion and exchange with intracellular and bone storage pools, are
tightly regulated tomaintain its serum level within a narrow range [1].
Elevated Pi levels have been linked to increased mortality in patients
with end-stage or even early stage chronic kidney disease [2,3].
Moreover, serum Pi levels in the upper normal range were found to be
associated with a signiﬁcant increase in mortality among individuals
with normal renal function [4].Dermatology, Department of
aifa 31096, Israel. Tel.: +972
. Sprecher).
l rights reserved.Although hyperphosphatemia is associated with many common
acquired conditions[5], only a few inherited (monogenic) disorders
manifesting with increased serum Pi levels are known [6]. Hyperpho-
sphatemic familial tumoral calcinosis (HFTC; MIM211900) is a rare
autosomal recessive condition characterized by the progressive de-
position of basic calcium phosphate crystals in peri-articular spaces
and soft tissues. HFTC is associated with marked hyperphosphatemia
in the face of inappropriately normal parathyroid (PTH) and normal or
slightly elevated levels of 1,25-dihydroxyvitamin D (1,25(OH)3D ) [7].
HFTCmay result frommutations in three different genes, encoding pro-
teins which are part of a common metabolic pathway. The ﬁrst muta-
tions associated with HFTC were initially reported in GALNT3 [8–15],
which encodes UDP-N-acetyl-alpha-D-galactosamine: polypeptide N-
acetylgalactosaminyl-transferarase 3 (ppGalNacT3), a glycosyltransfer-
ase that initiates mucin-type O-glycosylation [16]. Loss of function
mutations in the ﬁbroblast growth factor 23 (FGF23) gene were
subsequently found to also cause HFTC [17–20]. FGF23 codes for a
circulating molecule that promotes renal phosphate excretion by
decreasing phosphate re-absorption in the proximal renal tubule. In
addition, FGF23 further contributes to lowering circulating Pi levels by
Table 1
qRT-PCR oligonucleotide sequences
Sequence Size (bp) Gene
8F-CTCTATGTCTGGATGTTGG 109 GALNT3
9R-TCATGTTGAGCAGAGTATTC
1F- CTTGATTTGGGTACTCTTGG 122 GALNT1
2R-GAGGCTTTTGTACTGGCTCTAG
1F-GTGGAGCTCTTGGTCTCT 187 GALNT4
1R-TCGTTGAGCTGGAGTTTG
1F-ACGAGATGAATGAGGAGC 206 GALNT6
3R-CTGCGTCAGCTCTGAGT
12F-CTTTGGACACGCACGAC 131 MMP9
13R-GGATGTCATAGGTCACGTAGC
1F-GACGCTTCCATTTCTGCT 164 MMP8
2R-CGATCACATTAGTGCCATTC
1F-CAATGACATGACTCCAGAGC 274 FGF7
2R-CAACTGCCACTGTCCTG
3F-CGATCACATTAGTGCCATTC 127 ACTB
4R-AGGTGGACAGCGAGGCCAGGA
Fig. 1. Effect of Pi on PPGalNacT3/GALNT3 expression in human ﬁbroblasts. (a) hTERT
ﬁbroblasts were cultured for 24 h in the presence of increasing concentrations of Pi, and
ppGalNacT3 expression was ascertained by Western Blotting (upper panel). Results
were quantiﬁed by digital densitometry and the expression of ppGalNacT3 was
normalized to that of β-actin (Tina 2.10 g software; lower panel); hTERT ﬁbroblasts
were cultured for 24 h in the presence of (b) increasing concentrations of Pi or (c) for
increasing time periods in the presence of 3.5 mM Pi, and GALNT3 gene expression was
quantiﬁed by qRT-PCR. Results are expressed as % of expression relative to control cells+
standard deviation (SD).
62 I. Chefetz et al. / Biochimica et Biophysica Acta 1792 (2009) 61–67down-regulating the biosynthesis and increasing the catabolism of 1,25
(OH)3D [21,22], resulting in decreased 1,25(OH)3D levels. ppGalNacT3
was shown in vitro to be essential for FGF23 processing and secretion;
moreover, decreased ppGalNacT3 activity was found to result in
decreased levels of active FGF23 in the circulation [23–25]. Recently, a
mutation in a third gene, KL, was found to cause a phenotype verymuch
resembling HFTC [26,27]. KL encodes Klotho, which functions as a co-
receptor for FGF23 [28].
Although it is clear that ppGalNacT3, FGF23 or Klotho deﬁciency
affects Pi homeostasis systemically through dysregulation of phos-
phate reabsorption in the kidney (and possibly intestinalmucosa [29]),
little is currently known about non-systemic, kidney-independent,
features of ppGalNacT3 regulation andmetabolic effects. Interestingly,
ectopic calciﬁcation in HFTC is prominently (although not exclu-
sively) observed in cutaneous and subcutaneous tissues [7]. To in-
vestigate these aspects of ppGalNacT3 physiological roles, we used
in vitro systems and identiﬁed Pi as a major regulator of GALNT3
gene expression. In addition, we found out that as a consequence
of decreased ppGalNacT3 expression, ﬁbroblasts release increased
amounts of matrix metalloproteinases (MMPs), which have been
previously implicated in the pathogenesis of ectopic calciﬁcation
[30–33]. These data highlight the possible role of ppGalNacT3 in
peripheral tissues.
2. Materials and methods
2.1. Materials
Parathyroid Hormone Fragment 1-34 (PTH), 1α,25 Dihydroxyvita-
min D3, calcium chloride, and sodium phosphate dibasic dehydrate
were obtained from Sigma(St Louis, USA). Phosphonoformic acid (PFA)
was purchased fromMBL International (Woburn, MA, USA). FGF7 was
purchased from Pepro Tech (Rocky Hill, NJ, USA).
2.2. Cell cultures
Primary ﬁbroblast cell cultures were derived from punch biopsies
obtained from patients or healthy controls after having received their
written and informed consent according to a protocol reviewed and
approved by our Institutional Review Board. Primary human ﬁbro-
blasts immortalized with a hTERT-expressing retroviral vector
(hTERT-ﬁbroblasts) [34] were kindly provided by Dr. Sarah Selig. All
cells were maintained in DMEM-low glucose medium (Biological
Industries, Beith Haemek, Israel) supplemented with 10% fetal calf
serum, 1% L-Glutamine and 1% penicillin/streptomycin. Human
embryonic kidney cells (HEK 293) were maintained in DMEM/F12
medium with the same supplements.2.3. Quantitative RT-PCR (qRT-PCR)
For quantitative real-time PCR, cDNAwas synthesized from 1 μg of
total RNA extracted from cultured ﬁbroblasts using the Reverse-iT™
ﬁrst strand synthesis kit (ABgene, Epsom, UK) and random hexamers.
cDNA PCR ampliﬁcation was carried out using the Absolute™ QPCR
SYBR® Green Mix (ABgene) on a Rotor-Gene 3000 multi-ﬁlter system
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GALNT3, GALNT1, GALNT4, GALNT6, FGF7, MMP9, MMP8 and ACTB
(Table 1). To ensure the speciﬁcity of the reaction conditions, at the
end of the individual runs, the melting temperature (Tm) of the
ampliﬁed products was measured to conﬁrm their homogeneity.
Cycling conditions were as follows: 95 °C for 10 min; 95 °C for 10 s,
62 °C for 25 s and 72 °C for 15 s for a total of 40 cycles. Each samplewas
analyzed in triplicate. For quantiﬁcation, standard curves were
obtained using serially diluted cDNA ampliﬁed in the same real-time
PCR run. Results were normalized to ACTB mRNA levels, and for
conﬁrmation to GAPDH mRNA levels. After the quantiﬁcation
procedure, the products were resolved by 2.5% agarose gel electro-
phoresis to conﬁrm that the reaction had ampliﬁed the DNA
fragments of expected size.
2.4. Small interfering RNA (siRNA) transfection
Fibroblasts cells were grown to log phase, trypsinized and
maintained in 2 ml of growth medium without antibiotics into 6-
well tissue culture plates at 50% conﬂuence for 24 h. Six microliters of
lipofectamine (Invitrogen, Carlsbad, CA) were mixed in a total
volume of 500 μl of Opti-MEM medium with GALNT3-speciﬁc
siRNA or scrambled siRNA (20 nM) (Invitrogen) and added to the
cells for 6 h, at which time, the transfection medium was replaced
with complete growth medium. The GALNT3-speciﬁc siRNA duplex
used consisted of 5'-rGrGrCrArUrCrArAUrArCrArGrCUUrCrATT-3' and
5'-UrGrArArGrCUrGUrAUUrGrAUUrGrCrCTT3'.Fig. 2. Regulation of ppGalNacT3/GALNT3 in HEK293 cells. (a) HEK293 cells were cultured i
Western blotting and (b) qRT-PCR 24 h later; (c) To assess the effect of Pi transport on GALNT3
a known inhibitor of Pi transport (100% refers to the level of expression of GALNT3 in the pr
cultured with increasing concentrations of calcium and 1,25(OH)3D. Results in (b) and (d) a2.5. Western blotting
Cells were homogenized in lysis buffer (25 mM Hepes, 300 mM
NaCl, 1.5 mM MgCl2, 0.2 mM EDTA and protease inhibitors mix
including 1 mM PMSF, 1 mg/ml aprotinin and leupeptin; (Sigma, St
Louis, MO, USA). Following centrifugation at 10,000 g for 10 min at
4 °C, proteins were electrophoresed through a 10% SDS-PAGE and
transferred onto a nitrocellulose membrane (Trans-Blot Bio-Rad,
Hercules, CA, USA). After 1 h blocking with 1xTBS (20 mM Tris,
150 mM NaCl) with 5% skim milk and 0.01% Tween 20, blots were
incubated with a rabbit polyclonal anti-ppGalNacT3 antibody [35].
The speciﬁcity of this antibody has been demonstrated in previous
publications [36]. The blots were washed three times with TBS-
Tween (20 mM Tris HCl, 4 mM Tris base, 140 mM NaCl, 1 mM EDTA,
0.1% Tween-20). After incubation with secondary HRP-conjugated
anti-rabbit antibody (Sigma-Aldrich, St. Louis, MO, USA) and
subsequent washings, proteins were detected using the EZ-ECL
chemiluminescence detection kit (Biological Industries, Beit Haemek,
Israel).
In order to compare the amount of protein in the different
samples, the blots were reprobed with mouse monoclonal anti-
body to β-actin (ABcam, Cambridge, UK) and secondary HRP-
conjugated anti-mouse antibody (Sigma-Aldrich, St. Louis, MO,
USA). For quantitative determination of signal intensity, mem-
branes were scanned with ImageMaster VDS-Cl (Amersham
Pharmacia Biotech) and analyzed by digital densitometry (Tina
2.10 g software).n the presence of 1 mM or 3.5 mM Pi, and ppGalNacT3 expression was assessed by (a)
induction, wemaintained the cells in 3.5 mMPi in the presence (+) or absence (−) of PFA,
esence of 1 mM phosphate); (d) We also measured GALNT3 expression in HEK293 cells
re expressed as % of expression relative to control cells+SD.
Fig. 3. FGF7 expression in ppGalNacT3-deﬁcient human ﬁbroblasts. (a) hTERT
ﬁbroblasts were transfected with GALNT3-speciﬁc siRNA (siRNA) or a non-relevant
siRNA (control), and FGF7 expression was assessed by qRT-PCR after 3 days. Results are
presented as % of expression relative to control cells+SD; (b) Primary human ﬁbroblasts
derived from HFTC patients (HFTC) and control individuals (control) were assessed
for FGF7 expression by qRT-PCR. Results are given as % of expression relative to control
cells+SD; (c) FGF7 secretion in the medium obtained from patient (HFTC) and control
(control) primary ﬁbroblasts cultures was determined using a quantitative ELISA assay.
Results are expressed in pg/ml+SD.
64 I. Chefetz et al. / Biochimica et Biophysica Acta 1792 (2009) 61–672.6. FGF7 ELISA
Human FGF7 Eliza Quantikine kit (R and D, Minneapolis, MN, USA)
was used to detect FGF7 in the media of cultured primary ﬁbroblasts,
according to the manufacturer's instructions.
2.7. Gelatin zymography
Conditioned medium (CM) was collected from cultured ﬁbroblasts
maintained under serum-free conditions for 24 h and concentrated
1:20 using Vivaspin 6 concentrators (Sartorius, Goettingen, Germany).
The samples were then mixed with non-reducing SDS gel sample
buffer and applied without boiling to a 10% polyacrylamide gel
containing 0.1% SDS and 1 mg/ml gelatin. After electrophoresis, the
gels were washed in 50 mmol/l Tris-HCl (pH 7.5) containing 0.15 mol/l
NaCl, 5 mmol/l CaCl2, 0.02% NaN3, 0.25% Triton X-100 (three changes)
at room temperature, and then incubated in the same buffer without
Triton X-100 at 37 °C for 20 h. Proteins were stained by Coomassie
Brilliant Blue R-250 solution (Bio-Rad, Hercules, CA, USA).
2.8. MMP Proﬁling
MMP activity in the CMs was determined using Enzolyte MMP
ﬂuorometric assay kit (AnaSpec, Inc., San Jose, CA, USA). The CM
samples were incubated with MMP-speciﬁc peptide substrates
following the manufacturer's instructions. Cleavage of substrates by
MMPs removed the quenching effect of QXL520 on 5-carboxyﬂuor-
escein, resulting in increased ﬂuorescence with excitation at 490 nm
and emission at 535 nm [37]. Quantiﬁcation of signal emission was
performed using FLUOstar galaxy microplate reader (BMG Labtech
GmbH, Jena, Germany).
3. Results
3.1. Identiﬁcation of major regulators of ppGalNacT3/GALNT3 expression
in human cells
Although abnormal expression of ppGalNacT3 is clearly associated
with marked derangements of Pi metabolism [1,6,7,21,22], it is not
known whether Pi itself is involved in the regulation of ppGalNacT3/
GALNT3 expression. We therefore assessed the effect of increasing Pi
concentrations on ppGalNacT3 expression in human hTERT-ﬁbroblasts
in culture. ppGalNacT3 expression was strongly induced in response to
Pi (Fig. 1a) up to extracellular concentration of 5mM, which is known to
trigger apoptosis [38]. To determine the molecular basis of Pi-induced
ppGalNacT3 up-regulation,we assessedGALNT3 expression by qRT-PCR.
Consistent with the induction observed at the protein level, treatment
with Pi for 24 h at 3.5 mM up-regulated GALNT3 expression 2.4-fold,
whereas lower Pi concentrations had little effect (Fig. 1b). Cells were
then cultured in mediumwith 3.5 mM Pi for different time periods. We
observed an initial increase in GALNT3 RNA level 12 h after raising Pi
concentrations, reaching maximal induction after 22 h (Fig. 1c).
To determine whether the effect of Pi on GALNT3 expression is cell
lineage-speciﬁc, we assessed GALNT3 expression in HEK293 cells (a
cell line derived from human embryonic kidney tissue) exposed to
varying concentrations of Pi. Here again, a Pi dose-dependent increase
in ppGalNacT3 protein (Fig. 2a) and GALNT3 RNA (Fig. 2b) levels was
observed. GALNT3 gene induction was most most likely dependent
upon Pi inﬂux into the cells as the effect of Pi on GALNT3 expression
could be blocked by exposing the cells to phosphonoformic acid (PFA),
a known inhibitor of Pi transport [39] (Fig. 2c).
We also determine the effects of other molecules previously
implicated in the regulation of Pi circulating levels on GALNT3
expression. Although PTH lacked any signiﬁcant effect (data not
shown), both calcium and 1,25(OH)3D had a suppressive dose-
dependent effect on GALNT3 gene expression (Fig. 2d).3.2. GALNT3 down-regulation induces FGF7 expression
As mentioned above, the reason for the preferential accumulation
of calcium deposits in the skin and subcutaneous tissues in HFTC [7] is
still unclear. Recently, FGF7 (also known as keratinocyte growth
factor; KGF) was identiﬁed as capable of promoting Pi excretion
Fig. 4. GALNT3 down-regulation increases MMPs expression and activity. (a) Gelatinase activity in the culture mediumwas assessed by gel zymography, as described in Materials and
methods; (b) Human ﬁbroblasts were transfected with GALNT3-speciﬁc siRNA (siRNA) or a non-relevant siRNA (control), andMMP8 andMMP9 gene expressionwas assessed by qRT-
PCR. Results are given as % of expression relative to control cells+SD; (c) The same cells were comparatively assessed for MMP activity using a ﬂuorometric assay as described in
Materials and Methods; (d) Gelatinase activity in the culture medium of both types of cells was assessed by gel zymography.
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conditions are dermal ﬁbroblasts [41]. We therefore postulated that as
we found that Pi induces the expression of both GALNT3 (Fig. 1) and
FGF7 (Fig. 2S), GALNT3 gene expression may possibly inﬂuence the
expression of FGF7. To assess this possibility, we used siRNA
transfection to down-regulate the expression of GALNT3 in hTERT-
ﬁbroblasts (Fig. 1S). Signiﬁcantly increased FGF7 RNA levels were
found in cells transfected with GALNT3-speciﬁc siRNA as compared
with control siRNA-transfected cells (Fig. 3a). To assess the relevance
of these ﬁndings to the pathogenesis of HFTC, we also quantiﬁed FGF7
gene expression levels in primary ﬁbroblast cell cultures derived from
two HFTC patients. These individuals were previously shown to carry a
splice site mutation [15], which was found to result in complete
absence of the ppGalNAcT3 protein in the skin [42]. GALNT3 gene
transcription was decreased by 70% in primary ﬁbroblasts derived
from HFTC patients as compared with healthy controls (data not
shown). In contrast, FGF7 RNA expression was 3.5 fold higher in
patient cells than in control primary ﬁbroblasts (Fig. 3b). Accordingly,
HFTC patients’ primary ﬁbroblasts were found to secrete much higher
concentrations of FGF7 (80+10 vs 27+5 pg/ml), as compared with
control ﬁbroblasts (Fig. 3c).
3.3. GALNT3 down-regulation is associated with augmented
MMP activity
Among the various potential downstream paracrine effects of
FGF7, whose secretion seems to be triggered by GALNT3 down-
regulation, we noted that FGF7 has been shown to induce the activity
of several MMPs in different tissues [43–46], while MMPs have in turn
been previously implicated in the pathogenesis of ectopic calciﬁcation
[30–33]. Thus we ﬁrst assessed the capacity of FGF7 to trigger MMPs
secretion in dermal hTERT-ﬁbroblasts. Gelatin-zymography analysis ofCM collected 24 h after exposure to FGF7 revealed an increase in
gelatinase activity in response to FGF7 (Fig. 4a).
Since GALNT3 down-regulation induces FGF7 secretion (Fig. 3), and
FGF7 was found both in this (Fig. 4a) and previous studies [43–46] to
up-regulate MMP expression, we hypothesized that GALNT3 down-
regulation may also affect MMP activity in dermal hTERT-ﬁbroblasts.
Indeed, signiﬁcant up-regulation of MMP9 (1.7-fold) and MMP8 (7.9-
fold) mRNA levels was found upon down-regulation of GALNT3
expression by siRNA in human ﬁbroblasts (Fig. 4b) as well as in
HFTC primary ﬁbroblasts as compared with control cells (not shown).
Of note, increased Pi concentration did not affect the extent of gene
induction associated with GALNT3 down-regulation (Fig. 3S) and no
change in Pi extracellular concentration was observed 3 and 5 days
after siRNA transfection (not shown).
We then assessed human hTERT-ﬁbroblasts transfected with
GALNT3-speciﬁc siRNA for MMP activity using a panel of MMP-
speciﬁc ﬂuorescent substrates. We observed a signiﬁcant elevation in
the speciﬁc activities of MMP-8 (collagenase), MMP-9/2 (gelatinases)
and MMP-3 (but not MMP-1) in cells down-regulated for GALNT3
expression as compared with control ﬁbroblasts (Fig. 4c). Gel
zymography analysis demonstrated increased gelatinase activity in
CM obtained from GALNT3-down-regulated hTERT-ﬁbroblasts as
compared with control cells (Fig. 4d).
4. Discussion
Pi homeostasis has been shown to play an important role in human
physiology, determining to a large extent survival in selected groups
[5,47,48]. The study of rare inherited disorders often leads to insights
into physiological processes of general relevance [49]. In this regard,
the initial discovery of the cause of HFTC unveiled ppGalNacT3 as a
new element critical for maintaining Pi homeostasis [15]. Speciﬁcally,
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biosynthesis, which consists in the transfer of an N-acetyl-D-
galactosamine residue to a serine or threonine.
ppGalNacT3 deﬁciency has been shown to cause two distinct
diseases, HFTC [8–15,42] and hyperostosis hyperphosphatemia
syndrome [23,50,51], a recessive bone disorder. Thus, despite the
fact that O-linked oligosaccharide biosynthesis occurs ubiquitously,
ppGalNacT3 deﬁciency results in a very restricted spectrum of clinical
manifestations. Functional redundancy among glycosyltransferases
[52] has been invoked to explain this discrepancy [15]. However this
is unlikely to account alone for the preferential accumulation of
calcium deposits in the skin, suggesting a speciﬁc effect of
ppGalNacT3 deﬁciency in this tissue. We therefore sought to assess
the effects of GALNT3 down-regulation on dermal ﬁbroblasts in an in
vitro setting to address this issue in isolation from the systemic
effects of ppGalNacT3. We show here that Pi induces ppGalNacT3
expression in dermal hTERT-ﬁbroblasts and kidney epithelial cells.
The fact that Pi modulates ppGalNacT3 expression in peripheral
tissues may be interpreted to suggest that ppGalNacT3 plays a
physiological role in peripheral tissues of relevance to the pathogen-
esis of HFTC. Accordingly, we used cultures of HFTC patients’ primary
ﬁbroblasts as well as human hTERT-ﬁbroblasts transfected with
GALNT3-speciﬁc siRNA to mimic the consequences of decreased
ppGalNacT3 in an in vitro system. We discovered that decreased
GALNT3 expression results in increased secretion of both FGF7 and
MMPs, the expression of which is induced by FGF7. MMPs have been
linked to ectopic calciﬁcation in vascular tissues. In particular, MMP-9
was found to be up-regulated during vascular calciﬁcation, and
inhibition of MMPs activity was found to prevent calciﬁcation in the
same model [30,31]. Thus, the present data together with previous
observations suggest a causative role for MMPs in the pathogenesis of
ectopic calciﬁcation in skin tissues. A number of studies indicate that
Pi is able to induce MMPs expression in ﬁbroblasts and other tissues
[53–56], suggesting that both ppGalNacT3 deﬁciency and induced
MMP expression may have an additive detrimental (tissue-speciﬁc?)
effect. This hypothesis is further supported by the ﬁnding that
tetracyclines, which are known inhibitors of MMPs, have beneﬁcial
therapeutic effects in patients with cutaneous calcinosis [30,31,57,58].
This therapeutic response to tetracyclines is of particular importance
as a large panoply of other treatments aimed at reducing circulating
Pi levels shows very limited therapeutic beneﬁt to HFTC patients
[7,59–61].
Collectively, the present observations imply that in addition to the
well-known systemic effects of ppGalNacT3 deﬁciency on renal Pi re-
absorption, the pathogenesis of HFTC may also involve local/
peripheral processes. A number of natural modulators of ectopic
calciﬁcation, such as fetuin-A, matrix Gla protein and osteopontin,
may also play a local role in the pathogenesis of ectopic calciﬁcation in
various tissues including the skin [62–64]. The existence of such a
wide array of biological molecules and pathways contributing to the
formation of ectopic calciﬁcations suggests that variant alleles
encoding these proteins may account for the extensive clinical
heterogeneity observed in HFTC and related disorders.
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